Navigation Links
TargetEx Leads the European Cancer Research Consortium
Date:10/9/2009

BUDAPEST, Hungary, October 9 /PRNewswire/ -- TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the coordinator responsibilities of the European Cancer Research Consortium (CancerGrid) to TargetEx.

"This is very important for TargetEx" -an emerging biotech company in Hungary - "and an appreciation of our scientific potential " said Sandor Cseh, PhD., managing director. "We are excited to lead the consortium in the remaining phase of the project and we look forward to the exploitation of the exciting results and experience gathered in the effort of developing novel technologies and agents for cancer therapy."

"The CancerGrid consortium is an excellent combination of 11 European research-oriented companies and academic centers integrating their best practices and specific knowledge including AMRI (USA/Hungary), Inte:Ligand (Austria), Tallinn University of Technology (Estonia), University of Helsinki (Finland), GKI Economic Research Co.(Hungary), Computer and Automation Research Institute (Hungary), DAC Srl and University of Bari (Italy), University Pompeu Fabra (Spain) and Hebrew University of Jerusalem (Israel)" added Istvan Bagyi, PhD., the project coordinator of CancerGrid.

Cancer is one of the major causes of death worldwide and developing successful therapies is particularly challenging due to the high variability of cells, oncogenes and mutations. Developing tumor-cell specific cytotoxic agents is not only one of the aims of the CancerGrid project but also a "gentle" approache since they will attack only the cancer cells while not affecting the healthy cellular functions.

"The primary objective of the multidisciplinary FP6 project is to integrate various state-of-the art technologies including TargetEx' high-throughput differential cytotoxicity screening platform; in silico compound library selection methods and QSAR model building accelerated with distributed (grid) computing techniques. The ultimate goal of the project is to develop novel anti-cancer lead candidates together with a novel applicable research model which could cut the expenses and shorten the timeline of anti-cancer drug discovery" gave further details Gyorgy Dorman, PhD. the scientific coordinator of CancerGrid.

"Entering the anticancer research through leading this consortium corresponds to our strategic plan to extend the established molecular biology and assay development experience towards complex drug discovery research" concluded Dr. Cseh.

For further information, please visit the official web site of the CancerGrid project at http://www.cancergrid.eu as well as the TargetEx website: http://www.targetex.com. The project is partially financed by the Commission of the European Communities under the project number of LSHC-CT-2006-037559.

TargetEx (formerly known as RecomGenex) was founded in 2002. Currently it is an independent company offering complex services in the early phase of drug discovery. Core competences of the company are protein expression, cell and target-based assay development and HT screening. TargetEx offers to clients 'off the shelf' services and collaborative research and development. TargetEx recently launched a Hungarian Fragment Based Drug Discovery Consortium. The consortium is composed of two Hungarian biotech companies and a leading University division.

SOURCE Targetex Ltd


'/>"/>
SOURCE Targetex Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. UCSF researchers help crack parasite genome, identify drug leads
2. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
3. LightLab Imaging Leads Global Advancement of Intracoronary Imaging
4. Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale
5. Incorrectly cleaved protein leads to schizophrenia
6. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
7. Paul Capital Healthcare Leads Panel on Strategic Financing
8. Microsurgery on the brain of the fruit fly leads to new insights into irreparable nerve injuries
9. Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
10. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
11. Purdue leads center to simulate behavior of micro-electromechanical systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The ... three Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young ... Family Foundation and administered by the New York Academy of Sciences to honor ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):